Relevance of Plasma PCSK9 Concentration as a Biomarker in Acute Coronary Syndrome.
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 175
- 试验地点
- 2
- 主要终点
- Syntax score (for evaluate coronary damages) and plasmatic concentration of PCSK9
研究概览
简要总结
PCSK9 (Proprotein convertase subtilisin kexin type 9) plays a key role in LDL-cholesterol (LDLC) metabolism by inhibiting LDL receptor (LDLR) at post-transcriptional level. PCSK9 loss of function mutations are associated to decreased LDLC levels and a cardiovascular protection. In this context, the development of pharmacological inhibitors of PCSK9, in association with statins treatment, represents a major therapeutic issue for LDLC modulation. It was previously shown that PCSK9 plasmatic concentration correlated with plasmatic LDLC, TG and glucose concentrations. However, no data are available on predictive value of PCSK9 plasmatic level concerning coronary disease severity.
The main objective of this study is to determine whether plasmatic PCSK9 concentration is linked to coronary damage severity in patients with acute coronary syndrome.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Syntax score (for evaluate coronary damages) and plasmatic concentration of PCSK9
时间窗: Day 1, Day 2, Day 3, Day 4
Assessing the correlation between plasma concentration of PCSK9 and coronary damage severity in patients with acute coronary syndrome. Coronary lesions will be measured using the SYNTAX score (J0: admission day), and PCSK9 concentration will be evaluated using blood analysis (J0 (admission), J1, J2, J3 \& J4).
次要结局
- association between PCSK9 and metabolic/inflammatory factors(Day 1, Day 2, Day 3, Day 4)
- kinetic of PCSK9 for statin-treated patients(Day 1, Day 2, Day 3, Day 4)
- Correlation between PCSK9 and morbidity/mortality(Day 1, Day 2, Day 3, Day 4)
- kinetic of PCSK9 after intensive care(Day 1, Day 2, Day 3, Day 4)